Mount Yale Investment Advisors LLC Takes $181,000 Position in Amgen, Inc. (AMGN)

Mount Yale Investment Advisors LLC bought a new position in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,059 shares of the medical research company’s stock, valued at approximately $181,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ancora Advisors LLC purchased a new position in Amgen in the 1st quarter worth approximately $3,520,000. Kings Point Capital Management lifted its stake in Amgen by 10.3% in the 4th quarter. Kings Point Capital Management now owns 17,637 shares of the medical research company’s stock worth $3,067,000 after purchasing an additional 1,653 shares in the last quarter. Modera Wealth Management LLC lifted its stake in Amgen by 1.3% in the 4th quarter. Modera Wealth Management LLC now owns 26,252 shares of the medical research company’s stock worth $4,565,000 after purchasing an additional 331 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its stake in Amgen by 18.6% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 43,099 shares of the medical research company’s stock worth $7,495,000 after purchasing an additional 6,753 shares in the last quarter. Finally, AlphaStar Capital Management LLC purchased a new position in Amgen in the 4th quarter worth approximately $423,000. 78.31% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently commented on AMGN. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 price target on the stock in a research report on Thursday, April 5th. TheStreet lowered shares of Amgen from a “b-” rating to a “c+” rating in a research report on Wednesday, April 11th. BidaskClub lowered shares of Amgen from a “hold” rating to a “sell” rating in a research report on Saturday, March 24th. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price target on the stock. in a research report on Tuesday, March 6th. Finally, Royal Bank of Canada reduced their price target on shares of Amgen to $183.00 and set a “sector perform” rating on the stock in a research report on Wednesday, April 25th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $195.45.

Shares of Amgen opened at $184.59 on Friday, according to MarketBeat. The company has a market capitalization of $122.14 billion, a price-to-earnings ratio of 14.31, a PEG ratio of 2.29 and a beta of 1.38. The company has a debt-to-equity ratio of 2.14, a quick ratio of 3.60 and a current ratio of 3.88. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $201.23.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.23. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. Amgen had a return on equity of 35.80% and a net margin of 9.67%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.15 earnings per share. analysts predict that Amgen, Inc. will post 13.67 earnings per share for the current fiscal year.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $172.68, for a total value of $263,337.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 4,575 shares of company stock worth $809,851. 0.19% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply